<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053036</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-0174</org_study_id>
    <nct_id>NCT04053036</nct_id>
  </id_info>
  <brief_title>Effects of Drugs on Responses to Brain and Emotional Processes</brief_title>
  <acronym>MAT</acronym>
  <official_title>Effects of MDMA on Responses to Affective Touch in Individuals With a Range of Autistic Traits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of a psychostimulant on responses to affective touch in individuals with
      a range of autistic traits
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in responses to affective touch</measure>
    <time_frame>time 0 and approximately six weeks later</time_frame>
    <description>Participants will complete an affective touch task during which time they will rate pleasantness of touch</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo Then MDMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive MDMA (1.5 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDMA Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive MDMA (1.5 mg/kg) at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>Participants will be given 1.5mg/kg of MDMA</description>
    <arm_group_label>MDMA Then Placebo</arm_group_label>
    <arm_group_label>Placebo Then MDMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Participants will be given a placebo capsule that will only contain lactose.</description>
    <arm_group_label>MDMA Then Placebo</arm_group_label>
    <arm_group_label>Placebo Then MDMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 19 and 30 (no one under 130 lbs)

          -  Smokers smoking less than 25 cigarettes per week

          -  Have used ecstasy no more than 40 times with no adverse responses.

        Exclusion Criteria:

          -  High blood pressure

          -  Any medical condition requiring regular medication

          -  Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis

          -  Individuals with a history of dependence on stimulant drugs.

          -  Women who are pregnant or trying to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harriet de Wit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Bona</last_name>
    <phone>773-702-3560</phone>
    <email>mbona@yoda.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Bona</last_name>
      <email>mbona@yoda.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

